These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

681 related items for PubMed ID: 31918957

  • 1. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort.
    Tosoian JJ, Mamawala M, Epstein JI, Landis P, Macura KJ, Simopoulos DN, Carter HB, Gorin MA.
    Eur Urol; 2020 Jun; 77(6):675-682. PubMed ID: 31918957
    [Abstract] [Full Text] [Related]

  • 2. Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance.
    Mamawala MK, Meyer AR, Landis PK, Macura KJ, Epstein JI, Partin AW, Carter BH, Gorin MA.
    BJU Int; 2020 Jun; 125(6):861-866. PubMed ID: 32039537
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
    Maggi M, Cowan JE, Fasulo V, Washington SL, Lonergan PE, Sciarra A, Nguyen HG, Carroll PR.
    J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
    [Abstract] [Full Text] [Related]

  • 5. Multiparametric magnetic resonance imaging facilitates reclassification during active surveillance for prostate cancer.
    Fujihara A, Iwata T, Shakir A, Tafuri A, Cacciamani GE, Gill K, Ashrafi A, Ukimura O, Desai M, Duddalwar V, Stern MS, Aron M, Palmer SL, Gill IS, Abreu AL.
    BJU Int; 2021 Jun; 127(6):712-721. PubMed ID: 33043575
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study.
    Stavrinides V, Giganti F, Trock B, Punwani S, Allen C, Kirkham A, Freeman A, Haider A, Ball R, McCartan N, Whitaker H, Orczyk C, Emberton M, Moore CM.
    Eur Urol; 2020 Sep; 78(3):443-451. PubMed ID: 32360049
    [Abstract] [Full Text] [Related]

  • 12. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
    Panebianco V, Barchetti G, Simone G, Del Monte M, Ciardi A, Grompone MD, Campa R, Indino EL, Barchetti F, Sciarra A, Leonardo C, Gallucci M, Catalano C.
    Eur Urol; 2018 Jul; 74(1):48-54. PubMed ID: 29566957
    [Abstract] [Full Text] [Related]

  • 13. Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer.
    Chu CE, Lonergan PE, Washington SL, Cowan JE, Shinohara K, Westphalen AC, Carroll PR, Cooperberg MR.
    Eur Urol; 2020 Oct; 78(4):515-517. PubMed ID: 32631744
    [Abstract] [Full Text] [Related]

  • 14. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y.
    Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy.
    Pepe P, Cimino S, Garufi A, Priolo G, Russo GI, Giardina R, Reale G, Pennisi M, Morgia G.
    Scand J Urol; 2017 Aug; 51(4):260-263. PubMed ID: 28513296
    [Abstract] [Full Text] [Related]

  • 17. Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply?
    Hu JC, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Sonn G, Dorey FJ, Marks LS.
    J Urol; 2014 Aug; 192(2):385-90. PubMed ID: 24512956
    [Abstract] [Full Text] [Related]

  • 18. Multiparametric Magnetic Resonance Imaging Is Associated with Increased Medicare Spending in Prostate Cancer Active Surveillance.
    Macleod LC, Yabes JG, Fam MM, Bandari J, Yu M, Maganty A, Furlan A, Filson CP, Davies BJ, Jacobs BL.
    Eur Urol Focus; 2020 Mar 15; 6(2):242-248. PubMed ID: 31031042
    [Abstract] [Full Text] [Related]

  • 19. Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center.
    Carlsson S, Benfante N, Alvim R, Sjoberg DD, Vickers A, Reuter VE, Fine SW, Vargas HA, Wiseman M, Mamoor M, Ehdaie B, Laudone V, Scardino P, Eastham J, Touijer K.
    J Urol; 2020 Jun 15; 203(6):1117-1121. PubMed ID: 31909690
    [Abstract] [Full Text] [Related]

  • 20. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study.
    Luiting HB, Remmers S, Boevé ER, Valdagni R, Chiu PK, Semjonow A, Berge V, Tully KH, Rannikko AS, Staerman F, Roobol MJ.
    Eur Urol Oncol; 2022 Dec 15; 5(6):651-658. PubMed ID: 35437217
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.